Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.00
Bid: 38.00
Ask: 40.00
Change: 5.00 (15.15%)
Spread: 2.00 (5.263%)
Open: 33.00
High: 38.00
Low: 34.50
Prev. Close: 33.00
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

Tue, 02nd Jan 2024 12:01

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

The FTSE 100 index was down 29.34 points, 0.4%, at 7,703.90. The FTSE 250 was down 89.51 points, 0.5%, at 19,600.12, and the AIM All-Share was up 0.84 of a point, 0.1%, at 764.16.

The Cboe UK 100 was down 0.4% at 769.26, the Cboe UK 250 was down 0.5% at 17,076.23, and the Cboe Small Companies was down 0.4% at 14,939.05

"Markets got off to a cautious start on the first trading day of 2024, perhaps setting the tone for what could be a volatile year jam packed with political jostling ahead of crunch elections," said AJ Bell analyst Russ Mould.

The latest S&P Global UK manufacturing purchasing managers' index fell to 46.2 points in December, having risen to a seven-month high of 47.2 in November. The PMI fell further below the 50.0 point no-change mark, remaining below the threshold for the 17th consecutive month. The latest number landed below the flash estimate of 46.4.

S&P Global said the downturn accelerated as intakes of new work from both domestic and export clients declined. All five of the PMI sub-indices, new orders, output, employment, stocks of purchases and suppliers' delivery, have remained in deterioration.

"The latest S&P Global survey suggests the recent decline in manufacturing output probably has further to run...We doubt the headline index will recover materially in the new year, either," said Pantheon Macroeconomics analyst Gabriella Dickens.

"We think manufacturing output will continue to decline over the next few months. But given that the manufacturing sector accounts for only around 10% of overall economic output, and the services sector activity looks set to recover, we think a recession will be avoided."

Sterling was quoted at USD1.2668 on Tuesday at midday, down from USD1.2747 at the early London equities close on Friday.

In European equities, the CAC 40 in Paris was down 0.1%, while the DAX 40 in Frankfurt was up 0.2%.

In the eurozone, factories continued to undergo a sharp downturn in December, survey results from S&P Global showed, but noted that there are signs that the worst could be over.

The Hamburg Commercial Bank eurozone manufacturing purchasing managers' index rose to a seven-month high of 44.4 points in December from 44.2 in November. The reading was a touch higher than the flash estimate, which had forecast no change from the prior month.

The euro traded at USD1.0976 on Tuesday afternoon, lower than USD1.1074 around the same time on Friday. Against the yen, the dollar was quoted at JPY141.85, higher than JPY141.42.

Still to come on Tuesday is a US manufacturing PMI reading at 1445 GMT.

Stocks in New York are called to open lower. The Dow Jones Industrial Average was called down 0.3%, the S&P 500 index down 0.4%, and the Nasdaq Composite down 0.7%.

In the FTSE 100, AstraZeneca lost 0.6%.

The Cambridge-based pharmaceutical firm and Sanofi's long-acting monoclonal antibody treatment Beyfortus has been approved in China for the prevention of respiratory syncytial virus lower respiratory tract infection in neonates and infants.

AstraZeneca said the approval by China's National Medical Products Administration is based on three "pivotal" late-stage clinical trials and an "extensive" local clinical development programme. It is anticipated to be available during the upcoming 2024/25 RSV season.

Beyfortus was approved in the EU in October 2022 and received approval by the US Food & Drug Administration in July 2023 following the unanimous recommendation by the Antimicrobial Drugs Advisory Committee in June 2023.

AstraZeneca said regulatory applications are currently under review in Japan and "several other countries".

BT rose 0.9%, while WPP lost 1.1%, after Sky News on Monday reported that outgoing BT Chief Philip Jansen has been approached about becoming the next chair of WPP.

Jansen, who is set to leave BT in the spring, is reportedly one of a number of candidates to have been considered in recent weeks for the WPP chairmanship.

City sources on Monday said WPP's search was yet to reach an advanced stage and that there was no certainty that Jansen or WPP would opt to progress his candidacy further.

Airtel Africa rose 0.4%, after the telecommunications firm announced the retirement of Chief Executive Officer Segun Ogunsanya, naming Transformation Director Sunil Taldar as his successor.

Taldar joined the telecommunications company in October and will be appointed to the board as CEO and executive director following a transition period at the beginning of July.

At this time, Ogunsanya will formally retire but will be available to advise Chair Sunil Bharti Mittal, the board and incoming CEO Taldar for a 12-month period.

In the FTSE 250, Balfour Beatty rose 1.0% after the infrastructure construction firm said it appointed corporate brokers to manage an initial tranche of its 2024 share buyback programme, repurchasing up to GBP50 million or 63.2 million shares.

Balfour Beatty intends for this initial tranche to be completed by the end of June, while the total anticipated 2024 share buyback will be confirmed with the firm's full year results in March.

On AIM, LungLife AI surged 30%, after the developer of clinical diagnostic solutions designed to address the early detection of lung cancer announced the successful validation of its LungLB test for indeterminate lung nodules.

The LungLB test is a blood-based tool used by clinicians to help with earlier diagnosis of lung cancer nodules.

The diagnostic demonstrates a positive predictive value of 81% in distinguishing benign from cancerous lung nodules in patients with nodules smaller than 15 millimetres. This surpasses the current clinical standard of around 60%.

Sareum soared 22%, after the pharmaceutical company's co-development partner CRT Pioneer Fund entered into a development and commercialisation licence for SRA737 with an unnamed US biopharmaceutical company.

SRA737 is a clinical-stage oral, selective checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.

Gold was quoted at USD2,070.92 an ounce on Tuesday at midday, higher than USD2,065.02 on Friday. Brent oil was trading at USD78.53 a barrel, higher than USD77.56.

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
19 Apr 2024 12:16

IN BRIEF: Sareum falls as issues shares to RiverFort Global

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company - Issues 3.0 million new shares in the company to RiverFort Global Opportunities PCC Ltd. Issue is in line with facility announced in August. Says facility has an outstanding balance of GBP220,000.

Read more
4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
2 Apr 2024 17:35

TRADING UPDATES: Sareum ups retail offer; SThree nabs former ITV exec

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
28 Mar 2024 13:44

EARNINGS AND TRADING: Northamber loss widens; Ethernity contract boost

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
15 Mar 2024 13:11

Sareum allowed European patent for primary kinase inhibitor asset

(Sharecast News) - Biotechnology company Sareum announced on Friday that the European Patent Office had issued a notice of allowance for a patent concerning SDC‐1801, its primary TYK2/JAK1 kinase inhibitor currently undergoing clinical trials in Australia.

Read more
15 Mar 2024 12:46

Sareum Holdings touts new patent allowance for autoimmune therapy

(Alliance News) - Sareum Holdings PLC on Friday celebrated a new patent allowance for SDC-1801, which is a therapy designed to treat a range of autoimmune diseases.

Read more
12 Mar 2024 15:23

Sareum shares slump on widened loss and funding talks

(Alliance News) - Sareum Holdings PLC share fell on Tuesday, after it said it expects to report a widened interim loss.

Read more
15 Feb 2024 13:22

Sareum reports positive progress in psoriasis programme

(Sharecast News) - Sareum announced significant milestones in its phase 1a clinical trial for SDC-1801, its lead programme aimed at addressing autoimmune diseases such as psoriasis, on Thursday.

Read more
15 Feb 2024 11:20

Sareum hails safety profile for SDC-1801 after phase 1 trial

(Alliance News) - Sareum Holdings PLC on Thursday said SDC-1801 has the potential to achieve therapeutically effective dose levels with no serious adverse events, following a phase 1 trial.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
2 Jan 2024 13:54

Sareum shares jump on cancer drug licensing deal

(Sharecast News) - Shares in AIM-listed biotech group Sareum jumped by a fifth on Tuesday after its co-development partner for cancer treatment SRA737 signed a commercialisation licence agreement with a US biopharma company.

Read more
2 Jan 2024 10:05

AIM WINNERS & LOSERS: LungLife AI soars on test; Plexus falls on deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
2 Jan 2024 09:31

Sareum soars as partner agrees SRA737 licence with US biopharma firm

(Alliance News) - Sareum Holdings PLC shares surged on Tuesday, after it said its co-development partner CRT Pioneer Fund entered into a development and commercialisation licence for SRA737 with an unnamed US biopharmaceutical company.

Read more
14 Dec 2023 20:20

EARNINGS AND TRADING: CleanTech raises GBP520,000 in open offer

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.